Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases

被引:431
作者
van Burik, JAH
Hare, RS
Solomon, HF
Corrado, ML
Kontoyiannis, DP
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77030 USA
[2] Adv Biol, New Hope, PA USA
[3] Schering Plough Corp, Inst Res, Kenilworth, NJ 07033 USA
[4] Univ Minnesota, Minneapolis, MN USA
关键词
D O I
10.1086/500212
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To evaluate the activity of posaconazole for treatment of zygomycosis, a disease for which therapeutic options are limited, we conducted a retrospective study including 91 patients with zygomycosis ( proven zygomycosis, 69 patients; probable zygomycosis, 22 patients). Patients had infection that was refractory to prior antifungal treatment (n=81) or were intolerant of such treatment (n=10) and participated in the compassionate-use posaconazole ( 800 mg/day) program. The rate of success ( i.e., either complete or partial response) at 12 weeks after treatment initiation was 60%, and 21% of patients had stable disease. The overall high success and survival rates reported here provide encouraging data regarding posaconazole as an alternative therapy for zygomycosis.
引用
收藏
页码:E61 / E65
页数:5
相关论文
共 18 条
[1]   Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[2]   Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer [J].
Chamilos, G ;
Marom, EM ;
Lewis, RE ;
Lionakis, MS ;
Kontoyiannis, DP .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (01) :60-66
[3]   Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults [J].
Courtney, R ;
Wexler, D ;
Radwanski, E ;
Lim, J ;
Laughlin, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (02) :218-222
[4]   Oral bioavailability of posaconazole in fasted healthy subjects - Comparison between three regimens and basis for clinical dosage recommendations [J].
Ezzet, F ;
Wexler, D ;
Courtney, R ;
Krishna, G ;
Lim, J ;
Laughlin, M .
CLINICAL PHARMACOKINETICS, 2005, 44 (02) :211-220
[5]   Posaconazole as salvage therapy for zygomycosis [J].
Greenberg, RN ;
Mullane, K ;
van Burik, JAH ;
Raad, I ;
Abzug, MJ ;
Anstead, G ;
Herbrecht, R ;
Langston, A ;
Marr, KA ;
Schiller, G ;
Schuster, M ;
Wingard, JR ;
Gonzalez, CE ;
Revankar, SG ;
Corcoran, G ;
Kryscio, RJ ;
Hare, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (01) :126-133
[6]   Zygomycosis (mucormycosis): emerging clinical importance and new treatments [J].
Greenberg, RN ;
Scott, LJ ;
Vaughn, HH ;
Ribes, JA .
CURRENT OPINION IN INFECTIOUS DISEASES, 2004, 17 (06) :517-525
[7]   Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections [J].
Herbrecht, R .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (06) :612-624
[8]   Toward more effective antifungal therapy: the prospects of combination therapy [J].
Kontoyiannis, DP ;
Lewis, RE .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 126 (02) :165-175
[9]   Zygomycosis in a Tertiary-Care Cancer Center in the era of Aspergillus-active antifungal therapy:: A case-control observational study of 27 recent cases [J].
Kontoyiannis, DP ;
Lionakis, MS ;
Lewis, RE ;
Chamilos, G ;
Healy, M ;
Perego, C ;
Safdar, A ;
Kantarjian, H ;
Champlin, R ;
Walsh, TJ ;
Raad, II .
JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (08) :1350-1360
[10]   Zygomycosis in the 1990s in a tertiary-care cancer center [J].
Kontoyiannis, DP ;
Wessel, VC ;
Bodey, GP ;
Rolston, KVI .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (06) :851-856